Pfizer and Astellas Amend Clinical Research Protocols for Two Phase 3 Trials of Enzalutamide in Patients with Hormone-Sensitive Prostate Cancer
Go back to Pfizer and Astellas Amend Clinical Research Protocols for Two Phase 3 Trials of Enzalutamide in Patients with Hormone-Sensitive Prostate Cancer| Astellas Pharma Inc Unsponsored ADR (AMEX: ALPMY) | Delayed: 15.18 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $15.18 | 52 Week High | $19.40 | |||
| Open | $15.18 | 52 Week Low | $12.50 | |||
| Day High | $15.18 | P/E | N/A | |||
| Day Low | $15.18 | EPS | $0.00 | |||
| Volume | 52 | |||||
| Pfizer Inc. (NYSE: PFE) | Delayed: 27.66 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $27.66 | 52 Week High | $37.39 | |||
| Open | $27.66 | 52 Week Low | $28.25 | |||
| Day High | $27.66 | P/E | 16.76 | |||
| Day Low | $27.66 | EPS | $1.65 | |||
| Volume | 99,556 | |||||
